Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R2PD + lactobacillus casei is a combination microbial therapy consisting of the proprietary strain "R2PD" and the probiotic bacterium Lactobacillus casei. This oral formulation is being investigated for its potential to treat radiation-induced proctitis (radiation proctitis), a complication often seen in patients undergoing pelvic radiotherapy. The mechanism of action likely involves modulation of the gut microbiome, restoration of mucosal integrity, and reduction of inflammation through probiotic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on R2PD + lactobacillus casei.